Isle of Man vs Norway: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Isle of Man
0.0%
in 2024
Norway
0.0%
in 2024
Isle of Man rank
167th
Norway rank
167th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Isle of Man
- Norway
How they compare
Isle of Man currently reports 0.0% against 0.0% in Norway, a difference of 0.0%.
Across all 10 years both countries report, Norway has been ahead every year.
Isle of Man ranks 167th and Norway ranks 167th of 246 countries.
Norway has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Isle of Man | Norway | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.1% | 0.1% | 0.0% | Norway |
| 2020s | 0.0% | 0.0% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Isle of Man or Norway?
- Isle of Man, at 0.0% against 0.0% in Norway as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Isle of Man and Norway?
- 0.0%, with Isle of Man ahead.
- How many years of comparable data are there for Isle of Man and Norway?
- 10 years are reported by both, from 2015 to 2024.
- How do Isle of Man and Norway rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Isle of Man ranks 167th and Norway ranks 167th of 246 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.